Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause C-reactive protein abnormal? 34 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 34 reports of C-reactive protein abnormal have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.0% of all adverse event reports for DOXORUBICIN.

34
Reports of C-reactive protein abnormal with DOXORUBICIN
0.0%
of all DOXORUBICIN reports
0
Deaths
23
Hospitalizations

How Dangerous Is C-reactive protein abnormal From DOXORUBICIN?

Of the 34 reports, 23 (67.6%) required hospitalization, and 6 (17.6%) were considered life-threatening.

Is C-reactive protein abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 34 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause C-reactive protein abnormal?

METHOTREXATE (3,734) ADALIMUMAB (3,629) ETANERCEPT (3,592) ABATACEPT (3,402) LEFLUNOMIDE (3,279) TOCILIZUMAB (3,259) HYDROXYCHLOROQUINE (3,245) SULFASALAZINE (2,823) INFLIXIMAB (2,676) RITUXIMAB (2,608)

Which DOXORUBICIN Alternatives Have Lower C-reactive protein abnormal Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All C-reactive protein abnormal Reports All Drugs Causing C-reactive protein abnormal DOXORUBICIN Demographics